Human umbilical cord mesenchymal stem cells inhibit glioma growth

doi:10.3969/j.issn.2095-4344.2012.49.011

Abstract

Abstract:

BACKGROUND: Wnt signaling pathway is a key to occurrence and development of tumor. Several studies have demonstrated that Dickkopf-1 can block intracellular Wnt signalling transmission.

OBJECTIVE: To investigate the inhibitory effect and underlying mechanism of human umbilical cord mesenchymal stem cells on C6 glioma growth by a co-culture system in vitro.

METHODS: C6 glioma cells were cultured with human umbilical cord mesenchymal stem cells conditioned medium under different concentrations. Cell Counting Kit-8 and ?ow cytometry analysis were performed to investigate cell proliferation and cell cycle status. Western blotting was used to detect the expression of β-catenin and c-Myc in C6 cells treated with human umbilical cord mesenchymal stem cells conditioned medium. Enzyme-linked immunosorbent assay was adopted to examine the level of Dickkopf-1 secreted by human umbilical cord mesenchymal stem cells. Dickkopf-1 in human umbilical cord mesenchymal stem cells conditioned medium was neutralized by anti-Dickkopf-1 antibody. The effects of antibody neutralization were also determined by the above methods.

RESULTS AND CONCLUSION: Human umbilical cord mesenchymal stem cells could inhibit C6 cell expansion and arrest the cell cycle in G0-G1 phase. The expression levels of β-catenin and c-Myc were down-regulated in C6 cells after treatment with human umbilical cord mesenchymal stem cells conditioned medium. The levels of secreted protein Dickkopf-1 were positively correlated with concentrations of human umbilical cord mesenchymal stem cells conditioned medium. The inhibitory effect of human umbilical cord mesenchymal stem cells on C6 cell proliferation was enhanced as the concentration of Dickkopf-1 in human umbilical cord mesenchymal stem cells conditioned medium increased. When Dickkopf-1wasneutralized by anti-Dickkopf-1 antibody, the suppressing effect was attenuated. It demonstrated that human umbilical cord mesenchymal stem cells could inhibit glioma cell growth via secreting the soluble factors, such as Dickkopf-1.

CLC Number:

R394.2

Liang Shuo, Jiao Hong-liang,Chi Lian-kai, Shi Xin-yi, Liang A-ming, Tian Yi, Han Jiao-ling, . Human umbilical cord mesenchymal stem cells inhibit glioma growth[J]. Chinese Journal of Tissue Engineering Research, 2012, 16(49): 9179-9185.

Figures/Tables 6

References

[1] Donato V, Papaleo A, Castrichino A, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori. 2007;93(3):248-256.

[2] Kang SG, Kim JH, Nam DH,et al. Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir (Tokyo). 2005; 45(5): 232-238.

[3] Scheda A, Finjap JK, Tuettenberg J, et al. Ef?cacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori.2007; 93(1):31-36.

[4] Fagioli F, Berger M, Braeh del Preyer A, et al.Regression of metastatic oateosmcoma following non-myeloab]ative stem cell transplantation.Haenmtologiea. 2003; 88(5):16.

[5] Omuro Y, Matsumote G, Sasaki T, et al.Regression of nunresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.Bone Marrow Transplant.2003; 31(10):943-945.

[6] Kim S K, Cargioll TG, Machluf Mt, et al.PEX-Producing human neural stem cells inhibit tumor growth in a mouse g1ioma model．Clin Cancer Res. 2005; 11(16):5965-5970.

[7] Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma.J Exp Med.2006; 203(5):1235-1247.

[8] Jiao HL, Guan FX, Yang B,et al. Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1. Neurology India.2011; 59(2): 241-247.

[9] Yang F, Zeng Q, Yu G,et al．Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal.2006; 18(2):679-687.

[10] Baek SH, Kioussi C, Briata P. Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway. Proc Natl Acad USA.2003;100(6): 3245-3250.

[11] Brott BK, Sokol SY. Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol.2002; 22(17):6100-6110.

[12] Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognosticimplications. Cancer. 2004; 101(6):1345-1356.

[13] Byun T, Karimi M, Marsh JL, et al. Expression of secreted Wnt antagonists in gastrointestinal tissues: potential role in stem cell homeostasis. J Clin Pathol. 2005; 58(5):515-519.

[14] Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature.2001; 411(6835): 321-325.

[15] Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells.2007; 25(2) :319-331.

[16] Livraghi T, Meloni F, Frosi A, et al. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma. Oncol Res. 2005;15(7/8):399-408.

[17] Lu YR, Yuan Y, Wang XJ,et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther. 2008; 7(2):245-251.

[18] Qiao L, Xu ZL, Zhao TJ,et al. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signaling. Cancer Lett. 2008; 269(1): 67-77.

[19] Moon RT, Kohn AD, De Ferrari GV,et al. Wnt and β-catenin signalling: diseases and therapies.Nat Rev Genet. 2004; 5(9): 691-701.

[20] Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007; 19(2):150-158.

[21] Glennie S, Soeiro I, Dyson PJ,et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005; 105(7): 2821-2827.

[22] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006; 107(1): 367-372.

[23] Sotiropoulou PA, Perez SA, Gritzapis AD,et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells.2006; 24(1): 74-85.

[24] Zhu Y, Sun Z, Han Q, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia. 2009; 23(5):925-933.

[25] Meisel R, Zibert A, Laryea M,et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood.2004; 103(12): 4619-4621.

[26] Qiao L, Xu ZL, Zhao TJ, et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008;18(12): 500-507.

[27] Ramasamy R, Lam EF, Soeiro I, et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia.2007; 21(2):304–310.

[28] Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol.2006; 80(3): 267-274.

[29] Ma Y, Hao XM, Zhang S,et al. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat.2011; 80(1): 267-274.

[30] Studeny M, Marini FC, Dembinski JL.Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents, J. Natl. Cancer Inst.2004; 96 (21):1593–1603.